The Ultimate Price of Government Price Controls
 
Forbes | Sally Pipes
August 29, 2022

Democrats have nudged the U.S. healthcare system closer to Canadian-style socialism with their recently signed, and dubiously named, Inflation Reduction Act.

The IRA will impose a collection of price caps on prescription drugs. Canada has long forcibly controlled drug prices—and thereby deprived patients of access to cutting-edge care. The story will be the same in the United States, unless a future Congress and president roll back the IRA’s price controls before they take effect in 2026.


Read more. . .

What we need from our post-Fauci public health officials
 
Washington Examiner | Sally Pipes
August 23, 2022

Dr. Anthony Fauci announced this week that he will step down from his posts as director of the National Institute of Allergy and Infectious Diseases and chief medical adviser to President Joe Biden at the end of the year.

Just days earlier, Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention, announced a plan to reorganize the agency in response to its failures amid the COVID-19 pandemic.


Read more . . .

D.C. wants to make cancer patients wait for treatment
 
Boston Herald | Sally Pipes
August 27, 2022

The powers that be in Washington are renewing their campaign to gain greater control over Americans’ ability to access life-saving drugs.

Lawmakers and regulators alike have decided to wage war on one of the few components of our health care system that works well — the Food and Drug Administration’s accelerated approval process. This regulatory pathway has saved countless lives by speeding groundbreaking medicines to market. Obstructing that pathway would be folly.


Read more. . .

Inflation Reduction Act Bad Enough, Side Effects Worse
 
Newsmax | Sally Pipes
August 29, 2022

Among the recently passed Inflation Reduction Act’s most destructive provisions are the price controls it puts on prescription drugs through Medicare. These price controls are certain to have a chilling effect on pharmaceutical innovation in the years ahead.

But the precise manner in which the IRA will undermine biomedical research and development — and deprive future patients of breakthrough treatments — is worth considering. The law could end up discouraging exactly the kinds of scientific inquiry — and commercial development — that patients need.


Read more. . .